RSLS (Reshape Lifesciences) Other Long-Term Liabilities : $1.12 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Reshape Lifesciences Other Long-Term Liabilities?

Reshape Lifesciences's other long-term liabilities for the quarter that ended in Mar. 2025 was $1.12 Mil.

Reshape Lifesciences's quarterly other long-term liabilities declined from Sep. 2024 ($0.03 Mil) to Dec. 2024 ($0.02 Mil) but then increased from Dec. 2024 ($0.02 Mil) to Mar. 2025 ($1.12 Mil).

Reshape Lifesciences's annual other long-term liabilities increased from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.07 Mil) but then declined from Dec. 2023 ($0.07 Mil) to Dec. 2024 ($0.02 Mil).

Reshape Lifesciences Other Long-Term Liabilities Historical Data

The historical data trend for Reshape Lifesciences's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reshape Lifesciences Other Long-Term Liabilities Chart

Reshape Lifesciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Long-Term Liabilities

Get a 7-Day Free Trial

1.02

0.30

0.07

0.02

Reshape Lifesciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Other Long-Term Liabilities	Get a 7-Day Free Trial															0.05	0.05	0.03	0.02	1.12

Reshape Lifesciences Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Reshape Lifesciences Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Reshape Lifesciences's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Reshape Lifesciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Reshape Lifesciences Inc (NAS:RSLS) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

18 Technology Drive, Suite 110, Irvine, CA, USA, 92618

Website

https://www.reshapelifesciences.com

Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus. Geographically, the company operates in the United States, Australia, Europe, and the Rest of world, and the majority of its revenue is generated from the United States.

Executives

Thomas Stankovich	officer: Chief Financial Officer	1001 CALLE AMANECER, SAN CLEMENTE CA 92673
Paul F. Hickey	director, officer: President and CEO	2800 PATTON ROAD, ST. PAUL MN 55113
Barton P. Bandy	director	1001 CALLE AMANECER, SAN CLEMENTE CA 92673
Mcdougal Lori Courtney	director	2800 PATTON ROAD, ST. PAUL MN 55113
Arda Phd Minocherhomjee	director	C/O CHICAGO GROWTH PARTNERS, 303 W MADISON ST., SUITE 2500, CHICAGO IL 60606
Dan W Gladney	director	2800 PATTON ROAD, ST. PAUL MN 55113
Steven Boyd	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Gary Blackford	director	7700 FRANCE AVENUE SOUTH, EDINA MN 55435
Robert J Macdonald	officer: Chief Retail Officer	C/O OBALON THERAPEUTICS INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Daina Schmidt	officer: Vice President of Marketing	C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, SAN DIEGO CA 92008
Gilbert H Kliman	10 percent owner	C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022
Arnold L Oronsky	10 percent owner	C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022
Khaled Nasr	10 percent owner	467 FIRST STREET, SUITE 201, LOS ALTOS X1 94022
Interwest Partners X Lp	10 percent owner	C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022